HER2-Positive Early Stage Breast Cancer Recruiting Phase 1 / 2 Trials for Pertuzumab (DB06366)

Also known as: HER2-Positive Early Breast Cancer / HER2-positive early-stage breast cancer / Early Stage HER2+ Breast Cancer / HER2 Positive Early Breast Cancer

IndicationStatusPhase
DBCOND0063722 (HER2-Positive Early Stage Breast Cancer)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04750122Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer PatientsTreatment